Fresenius Medical Care AG

- Fresenius Medical Care does not provide specific details on current or future fundraising through debt or equity in the Q3 2025 earnings call. - The company mentions a disciplined use of cash aligned with a new capital allocation framework aimed at reigniting value creation. - They report repurchasing shares (equity buyback) totaling EUR 188 million through October 31, 2025. - They have invested EUR 312 million in strengthening ownership in their Value-Based Care asset Interwell Health, reflected in financing cash flow. - There is no mention of new debt issuance or equity fundraising plans. - The net leverage ratio is strengthened to 2.6x, well within their target range (2.5 to 3x), indicating financial stability that may reduce the immediate need for new debt. - The company remains flexible and agile in planning due to ongoing healthcare policy uncertainties but has not indicated plans for new fundraising.

- Investment of EUR 312 million in Q3 to strengthen ownership in Value-Based Care asset Interwell Health, reinforcing leadership in renal Value-Based Care and positioning for long-term profitable growth (Page 4). - Continued rollout and early deployment of HVHDF machines; adding clinics steadily with plans for large-scale launch in 2026 to transition clinic network (Pages 3, 9, 11). - Ongoing execution of the FME25+ program aimed at manufacturing and supply chain footprint optimization, delivering sustainable savings and supporting margin expansion (Pages 5, 7, 9). - Share buyback program underway with repurchase of 3.6 million shares by end of September (Page 4). - No explicit mention of further capital expenditure guidance; 2026 planning ongoing with several moving parts, to be disclosed with 2026 full-year results (Pages 5, 10).

- **U.S. Same Market Treatment Growth**: Expected to improve positively starting in 2025, with notable ramp-up in 2026 due to the rollout of HVHDF and improved referrals. - **Phosphate Binders**: Growth in the pharma business driven by phosphate binders is anticipated but with volume and pricing uncertainties moving into 2026. - **Care Delivery Growth Components**: Favorable rate mix, reduced implicit price concessions, and phosphate binder contributions on track to positively impact revenues and margins into Q4 and beyond. - **Volume Growth**: Seen as increasingly important, especially in the U.S., with localized growth opportunities in certain regions and plans to optimize clinic footprint where growth is limited. - **Value-Based Care**: Expected to continue strong revenue growth, driven mainly by contracting growth and member months, although earnings fluctuate due to contract-related revenue recognition. - **Overall Outlook for 2026**: Planning ongoing with multiple moving parts, including volume, price erosion, subsidies, and reimbursement; outlook to be provided with full-year results in February.

- Fresenius Medical Care expects continued strong earnings growth with operating income growth accelerating to 28% in Q3 2025. - Operating income margin expanded from 9.9% to 11.7% in Q3, reaching the top end of their 2025 target band. - Full year 2025 operating income guidance range is confirmed, with further acceleration expected in Q4 (the strongest quarter). - The FME25+ program delivered sustainable savings of EUR 174 million for 2025, supporting profitability. - Phosphate binders and FME25+ program contribute significant positive earnings impact, helping offset volume headwinds and currency effects. - For 2026, the company is still in planning and cautious due to various moving parts (phosphate binder mix evolution, pricing, ACA subsidy uncertainty). - They expect the ramp-up of HDF treatment in 2026 to contribute positively to operating leverage and margins. - A clear focus on volume growth, operational efficiencies, and new therapies supports confidence in long-term earnings growth.

The provided pages of the document do not contain any specific information or figures related to the current order book or expected/pending orders. The discussion focuses mainly on: - The rollout and expected impact of HDF (High Volume Hemodiafiltration). - Financial performance including revenue growth, EBIT guidance, and operating income. - Treatment growth, margin improvements, and revenue cycle management. - Updates on segments such as Care Delivery, Care Enablement, and Value-Based Care. - Phosphate binder contributions and market treatment growth. - Outlook and planning for 2026. No explicit details or quantitative data about order books or pending orders are mentioned in the available transcript.